Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Crescita Therapeutics Inc CRRTF


Primary Symbol: T.CTX

Healthcare
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial... see more

Recent & Breaking News (TSX:CTX)

Crescita Reports Second Quarter 2022 Results

Business Wire August 10, 2022

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Business Wire May 12, 2022

Crescita Reports First Quarter 2022 Results

Business Wire May 11, 2022

Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 21, 2022

Crescita Reports Q4 and Fiscal 2021 Results

Business Wire March 23, 2022

Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid

Business Wire December 15, 2021

Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

Business Wire December 13, 2021

Crescita Reports Third Quarter 2021 Results and Appoints New Board Member

Business Wire November 11, 2021

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

Business Wire September 9, 2021

Crescita Acquires Minority Interest in The Best You®

Business Wire September 7, 2021

Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®

Business Wire August 18, 2021

Crescita Reports Second Quarter 2021 Results and Provides Corporate Update

Business Wire August 11, 2021

Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

Business Wire June 28, 2021

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Business Wire May 12, 2021

Crescita Reports First Quarter 2021 Results

Business Wire May 11, 2021

Crescita Therapeutics to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 13, 2021

Crescita Reports Q4 and Fiscal 2020 Results

Business Wire March 24, 2021

Crescita Announces Filing of New Medical Device License

Canada NewsWire January 21, 2021

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

Canada NewsWire November 26, 2020

Crescita Reports Third Quarter 2020 Results

Canada NewsWire November 12, 2020